Advanced Esophagogastric Cancer (EGC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The second most common cause of cancer deaths worldwide is advanced esophagogastric cancer (EGC), a heterogeneous group of malignancies. Although surgery combined with chemotherapy and/or radiation is the mainstay of treatment for early-stage disease, the majority of patients with advanced disease still have poor survival rates. The sixth leading cause of cancer-related death is esophagogastric cancer (EGC), which is the seventh most prevalent cancer in the world. It is endemic throughout much of the world, particularly in third-world nations, and it is the fourth most common reason for cancer-related death. The majority of EGC patients who are ineligible for potentially curative treatment still receive palliative chemotherapy, though targeted therapy has additional benefits. Anthracyclines, fluoropyrimidines, taxanes, and platinum-based agents are among the combinations of chemotherapy that have been subjected to the most thorough testing. Combination chemotherapy has been shown to be more effective than single-agent chemotherapy.

Description

A diverse group of cancers collectively known as advanced esophagogastric cancer (EGC) account for the second most common cause of cancer-related death worldwide. The mainstay of treatment for early-stage disease is surgery combined with chemotherapy and/or radiation, but the majority of patients with advanced disease continue to have poor survival rates. A significant contributor to cancer-related fatalities is Esophageal cancer (EGC), which includes gastroesophageal adenocarcinoma (EGJ) and distal gastric cancer (GC). Epidermal growth factor receptor 2 (ERRB2) negative patients who have metastatic status, a median survival of less than 11 months, and optimal palliative care should receive chemotherapy.

Advanced Esophagogastric Cancer (EGC) (Epidemiology)

The sixth leading cause of cancer-related death is esophagogastric cancer (EGC), which is the seventh most prevalent cancer in the world. It is endemic throughout much of the world, particularly in third-world nations, and it is the fourth most common reason for cancer-related death. The highest infection rates are found in East Asia, Southern Africa, and East Africa, while the lowest rates for both men and women are found in West Africa, North Africa, and Central America. The incidence of esophageal cancer can reach as high as 800 cases per year in some areas, including northern Iran, southern Russia, and northern China (commonly referred to as the "esophageal cancer belt"). a hundred thousand. Although the primary risk factors in these regions are unknown, a poor diet, including a deficiency in fruits and vegetables and a preference for hot beverages, may be a contributing factor. Squamous cell carcinoma makes up 95% of all esophageal cancers worldwide, in contrast to the US.

Advanced Esophagogastric Cancer (EGC) -Current Market Size & Forecast Trends

The market for advanced esophagogastric cancer (EGC) is projected to grow significantly, with estimates indicating a value of approximately USD 14.90 billion in 2023 and expected to reach around USD 25.99 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.26% during this period. This growth is driven by the increasing prevalence of esophageal and gastric cancers, advancements in treatment options including immunotherapy and targeted therapies, and rising awareness about early detection and treatment. orth America is anticipated to dominate the market due to its advanced healthcare infrastructure, while regions like Asia-Pacific are expected to see rapid growth due to rising incidence rates. Overall, the advanced esophagogastric cancer market is well-positioned for substantial growth through 2035 as new therapies and treatment strategies continue to emerge.

Even though targeted therapy has additional advantages, the majority of EGC patients who cannot receive potentially curative treatment still receive palliative chemotherapy. One of the chemotherapy regimens that has undergone the most extensive testing is the combination of anthracyclines, fluoropyrimidines, taxanes, and platinum-based agents. It has been demonstrated that combination chemotherapy is more efficient than chemotherapy using a single agent. Platinum-based drugs like 5-FU/leucovorin/oxaliplatin (e.g., cisplatin) have been shown to have efficacy data (mOS 10.7 months; mPFS 5.8) and toxicity profiles. First-line treatment for advanced HER2-negative disease was determined to be (, FLO or FOLFOX). choice. rate ORR of 34% for the month. Three trianthracyclines, epirubicin, oxaliplatin, and capecitabine (EOX), also demonstrated comparable efficacy (mos 11.2 months; mPFS 7 months; ORR 47.9%), but due to anti-anthracene, concerns about the efficacy of the ring drug are less common in the US. To further improve the effectiveness of first-line therapy in the HER2-positive group (13.08 months; mPFS 6.5 months; ORR 47%), trastuzumab was added to cisplatin/5-FU. The combination of 5-FU, leucovorin, and irinotecan (FOLFIRI) is still a successful first-line therapy for patients who cannot receive platinum. Ramucirumab alone or in combination with paclitaxel is the preferred therapy for adenomas in second-line, according to data from the phase 3 REGARD and RAINBOW trials (discussed later in the section on targeted therapy). Other drugs, such as docetaxel and/or irinotecan, have a moderate clinical activity and a modest survival improvement over best supportive care. In light of recent results from the phase 3 TAGS study evaluating its efficacy in treating patients who had received a lot of prior treatment, trifluridine/tipiramate (TAS-102) has been approved by the FDA as a third-line therapy for EGC. On the other hand, trifluridine/tipiramide offers chemotherapy patients an extra option with controllable toxicity.

Report Highlights

Advanced Esophagogastric Cancer (EGC) - Current Market Trends

Advanced Esophagogastric Cancer (EGC) - Current & Forecasted Cases across the G8 Countries

Advanced Esophagogastric Cancer (EGC) - Market Opportunities and Sales Potential for Agents

Advanced Esophagogastric Cancer (EGC) - Patient-based Market Forecast to 2035

Advanced Esophagogastric Cancer (EGC) - Untapped Business Opportunities

Advanced Esophagogastric Cancer (EGC) - Product Positioning Vis-a-vis Competitors' Products

Advanced Esophagogastric Cancer (EGC) - KOLs Insight